Marquette Asset Management LLC Takes $142,000 Position in Kinnate Biopharma Inc. (NASDAQ:KNTE)

Marquette Asset Management LLC acquired a new position in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 59,961 shares of the company’s stock, valued at approximately $142,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Citigroup Inc. boosted its position in shares of Kinnate Biopharma by 53,138.6% in the 3rd quarter. Citigroup Inc. now owns 420,585 shares of the company’s stock valued at $589,000 after purchasing an additional 419,795 shares during the period. Acadian Asset Management LLC lifted its stake in Kinnate Biopharma by 71.0% during the third quarter. Acadian Asset Management LLC now owns 736,686 shares of the company’s stock valued at $1,030,000 after buying an additional 305,884 shares in the last quarter. Acuitas Investments LLC purchased a new stake in Kinnate Biopharma during the fourth quarter valued at about $687,000. Pale Fire Capital SE boosted its holdings in shares of Kinnate Biopharma by 196.3% in the third quarter. Pale Fire Capital SE now owns 70,174 shares of the company’s stock worth $98,000 after buying an additional 46,492 shares during the period. Finally, BML Capital Management LLC purchased a new position in shares of Kinnate Biopharma in the fourth quarter worth approximately $1,110,000. 80.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

KNTE has been the subject of a number of recent analyst reports. Stifel Nicolaus raised their price objective on shares of Kinnate Biopharma to $2.59 and gave the stock a “hold” rating in a research note on Monday, February 26th. William Blair cut Kinnate Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, February 16th. Finally, Wedbush reiterated a “neutral” rating and set a $2.00 price target on shares of Kinnate Biopharma in a report on Wednesday, January 17th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.15.

Kinnate Biopharma Price Performance

Kinnate Biopharma stock traded down $0.01 during trading hours on Friday, hitting $2.65. The company had a trading volume of 2,812,200 shares, compared to its average volume of 418,678. Kinnate Biopharma Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $7.18. The firm has a market capitalization of $125.13 million, a P/E ratio of -0.95 and a beta of 1.38. The firm’s fifty day moving average is $2.60 and its 200-day moving average is $2.24.

About Kinnate Biopharma

Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.